BPC-157 vs KPV

Side-by-side comparison of BPC-157, KPV — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute BPC-157 Body Protection Compound-157 Recovery KPV KPV (Lys-Pro-Val) — Alpha-MSH Tripeptide Recovery
Basics
Molecular type Gastric PentadecapeptideAlpha-MSH C-terminal Tripeptide
Amino acids 153
Molecular weight 1,419.5 Da355.4 Da
Half-life ~4 hrs (SC)Short (hours)
Route(s) Subcutaneous, Intramuscular, Oral (research only)Subcutaneous, Oral (GI conditions), Topical
Mechanism & Research
Primary mechanism BPC-157 exerts its primary effects through upregulation of the nitric oxide (NO) signalling pathway. By promoting NO synthase activity, it drives vasodilation and angiogenesis at injury sites, accelerating the delivery o… KPV binds melanocortin receptors (MC1R and MC3R) expressed on immune cells, epithelial cells, and neurons. Receptor activation suppresses NF-κB-mediated pro-inflammatory cytokine production (TNF-α, IL-6, IL-8) and drives…
Research status Research Compound Research Compound
Evidence summary The majority of BPC-157 research is preclinical (animal and in vitro). No large-scale randomised controlled trials in humans have been published as of 2026. The FDA's 2024 assessment noted insufficient human safety and e… KPV has robust preclinical data for inflammatory bowel conditions (Crohn's disease, ulcerative colitis models) and wound healing. Oral nanoparticle formulations have been developed to improve colonic delivery.
Protocol & Dosing
Typical dose 200–500 mcg per injection500 mcg–2 mg/day (SC); variable oral dosing
Frequency Once or twice dailyOnce or twice daily
Duration 4–12 weeks4–8 weeks
Timing Near injury site when possibleAny time; pre-meals for GI applications
Safety
Common side effects
  • Injection site redness or bruising
  • Mild nausea (oral form)
  • Transient dizziness
  • Warmth at injection site
  • Injection site redness (SC)
  • Mild skin darkening (possible — MC1R activity)
  • Headache (rare)
Contraindications
  • Active malignancy (theoretical growth stimulation concern)
  • Pregnancy (no safety data)
  • Concurrent anticoagulant therapy (caution)
  • Known melanocortin sensitivity
  • Pregnancy (insufficient data)
  • Active melanoma (MC1R concern)
Anti-doping Prohibited (WADA S0) Not Prohibited
Deeper reading
Related peptides TB-500, GHK-Cu, KPV, Pentadeca Arginate BPC-157, LL-37, TB-500
Full profile Read full BPC-157 profile → Read full KPV profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.